

《頭頸癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 113/12/30	115 年版 修訂日 114/12/08
Primary Systemic Therapy + Concurrent Radiotherapy	Primary Systemic Therapy + Concurrent Radiotherapy ■ 刪除 Paclitaxel + Cisplatin Q3W*6 ■ 刪除 Cisplatin + 5FU Q3W*6
Neoadjuvant immunotherapy	Neoadjuvant immunotherapy ■ 新增 Pembrolizumab + Cisplatin
Recurrent, Unresectable, or Metastatic Disease	Recurrent, Unresectable, or Metastatic Disease ■ 新增 Erdafitinib

《頭頸癌抗癌藥物治療指引》

Head and Neck (Non-Nasopharyngeal) Cancers

Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary

Primary Systemic Therapy + Concurrent Radiotherapy

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	1, 2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* $\rightarrow$ 250	90* $\rightarrow$ 60 mins	d1	QW	8	3

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	70	1 hr	d1-4	Q3W	3	4
5-FU	600	22-24 hrs	d1-4	Q3W	3	

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	70	1 hr	d1-5	Q4W	2	5
5-FU	600	22-24 hrs	d1-5	Q4W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	800	22-24 hrs	d1-5	Q2W	6	6
Hydroxyurea	1g PO Q12H		11 doses	Q2W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	30	≥ 1 hr	d1	QW	7	6
Cisplatin	20	≥ 1 hr	d2	QW	7	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	7
5-FU	1000	22-24 hrs	d1-5	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	60	≥ 4 hrs	d1	Q2W	7	7
5-FU	800	22-24 hrs	d1-5	Q2W	7	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	5	22-24 hrs	d1-4	Q4W	2	19
5-FU	250	22-24 hrs	d1-4	Q4W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	100	1 hr	d1	QW	8	8
Paclitaxel	40	≥ 1 hr	d1	QW	8	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	4	9, 10

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	25	≥ 30 mins	d1-5	QW	5	16

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W	6	29
UFUR	800 mg* PO QD		d1-14	Q2W	6	
Leucovorin	60 mg PO QD		d1-14	Q2W	6	

*Or 300 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	2	30
5-FU	400	22-24 hrs	d1-4	Q4W	2	
Leucovorin	90	22-24 hrs	d1-4	Q4W	2	

Induction/Sequential Chemotherapy and Neoadjuvant Immunotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	3-4	22, 24
Cisplatin	75	≥ 4 hrs	d1	Q3W	3-4	
5-FU	750	22-24 hrs	d1-5	Q3W	3-4	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	3	23
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	
5-FU	1000	22-24 hrs	d1-4 [#]	Q3W	3	

[#] May extend to day 5 if tolerable

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	3	30
5-FU	600	22-24 hrs	d1-4	Q4W	3	
Leucovorin	90	22-24 hrs	d1-4	Q4W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	3	25
Cisplatin	100	≥ 4 hrs	d2	Q3W	3	
5-FU	500	22-24 hrs	d2-6	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	6	8, 34
Paclitaxel	135	≥ 3 hrs	d1	QW	6	
Carboplatin	AUC 2	≥ 3 mins	d1	QW	6	

*1st dose 400 mg/m² then followed by 250 mg/m²

Stage III-IVa cancer (with PD-L1 (CPS) ≥ 1): Oral cavity, p 16-negative oropharynx, hypopharynx, and larynx

Neoadjuvant Pembrolizumab followed by adjuvant Pembrolizumab/RT (with Cisplatin if extranodal extension and/or positive margin) followed by adjuvant Pembrolizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	2	31, 32
Followed by Surgical tumor ablation						
Followed by Pembrolizumab	200 mg	≥ 30 mins	d1 of RT	Q3W	3 with RT	
± Cisplatin*	75	≥ 4 hrs	d1 of RT	Q3W	3 with RT	
Followed by Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	12	

*If extranodal extension and/or positive margin

Systemic Therapy/RT Following Induction Therapy, or Combination Chemotherapy for Recurrent/Persistent Disease

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 1.5	≥ 30 mins	d1	QW	7	26

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	7	27

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W	6	28
UFUR	800 mg* PO QD		d1-14	Q2W		
Leucovorin	60 mg PO QD		d1-14	Q2W		

*Or 300 mg/m²

Postoperative Chemoradiation

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	75-100	≥ 4 hrs	d1	Q3W	3	11-13, 15

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	30*	≥ 2 hrs	d1	QW	6	14, 33

*or 50 mg for 7-9 cycles with RT

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	#	20
Cisplatin	30	≥ 2 hrs	d1	QW	#	

*1st dose 400 mg/m² then followed by 250 mg/m²

1st cycle before RT and continued cycles during RT

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	#	20
Docetaxel	15	≥ 30 mins	d1	QW	#	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

#1st cycle before RT and continued cycles during RT

參考文獻

1. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of radiotherapy OG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845-852.
2. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92-98.
3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
5. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145-153.
6. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864.

7. Taylor S, Murthy A, Vannetzel J, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. *J Clin Oncol* 1994;12:385-395.
8. Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. *Int J Radiat Oncol Biol Phys* 2000;47:49-56.
9. Beckmann GK, Hoppe F, Pfreundner L, et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. *Head Neck* 2005;27:36-43.
10. Medina JA, Rueda A, de Pasos AS, et al. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. *Radiother Oncol* 2006;79:34-38
11. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 2004;350:1937-1944
12. Bernier J, Dommenege C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 2004;350:1945-1952
13. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and radiotherapyOG (#9501). *Head Neck* 2005;27:843-850.
14. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. *Int J Radiat Oncol Biol Phys* 1996 Dec 1;36:999-1004.
15. Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the radiotherapyOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 2012;84:1198-1205.
16. Jeremic B, Milicic B, Dagovic A, et al. Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck. *J Clin Oncol*, 2004, 22:3540-3548

17. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. *Clin Adv Hematol Oncol* 2007;5: 79-81
18. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2005;23:3562-3567
19. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. *Br J Cancer*. 2005;93:279-286
20. Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group radiotherapy OG-0234. *J Clin Oncol*. 2014;32:2486-2495
21. Fietkau R, Lautenschläger C, Sauer R, et al. Postoperative concurrent radio-chemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96–32006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)24,(18S) 2006: 5507
22. Vermorken JB, Remenar E, van Herpen C, et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med* 2007;357(17):1695-1704.
23. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 2007;357(17):1705-1715
24. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst* 2009;101:498-506
25. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol* 2005;23:8636-8645.
26. Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM):

- a randomised phase 3 trial. *Lancet Oncol.* 2013;14:257-4264
27. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. *J Clin Oncol* 2013;31:853-859.
 28. Hung-Ming Wang, Cheng-Su Wang, Jen-Shi Chen, et al. Cisplatin, tegafur, and leucovorin: A moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. *Cancer* 2002; 94 (11): 2982-2995.
 29. Wang HM, Hsu CL, Hsieh CH, et al. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. *Biomed J* 2014;37(3):133-40.
 30. Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. *J Clin Oncol.* 1995 Oct;13(10):2620-8. doi: 10.1200/JCO.1995.13.10.2620. PMID: 7595716.
 31. Uppaluri R, Haddad RI, Tao Y, et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. *N Engl J Med.* 2025;393(1):37-50. doi:10.1056/NEJMoa2415434
 32. Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clin Cancer Res.* 2020;26(19):5140-5152. doi:10.1158/1078-0432.CCR-20-1695
 33. Noronha V, Joshi A, Patil VM, et al. Once-a-Week versus once-every-3-weeks cisplatin chemoradiation for Locally advanced head and neck cancer: a phase III randomized noninferiority trial. *J Clin Oncol* 2017;Jco2017749457.
 34. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. *J Clin Oncol* 2010;28:8-14.

Recurrent, Unresectable, or Metastatic (incurable) Disease

First-line Therapy

Combination Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Cisplatin	100	≥ 4 hrs	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Carboplatin	AUC 5	1 hr	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m² then followed by 250 mg/m²

Immunotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	34 (24 mo)	18
Cisplatin	100	≥ 4 hrs	d1	Q3W	6	
5-FU	1000	22-24 hrs	d1-4	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	34 (24 mo)	18
Carboplatin	AUC 5	1 hr	d1	Q3W	6	
5-FU	1000	22-24 hrs	d1-4	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	34 (24 mo)	18, 19

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Cisplatin	75-100	≥ 4 hrs	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Carboplatin	AUC 5	1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Cisplatin	100	≥ 4 hrs	d1	Q3W	6	
Docetaxel	65	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Carboplatin	AUC 5-6	1 hr	d1	Q3W	6	
Docetaxel	65	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		21
Cetuximab	400* → 250	90* → 60 mins	d1	QW		

*1st dose 400 mg/m² then followed by 250 mg/m²

Other Combination Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	65	1 hr	d1	Q3W		2
Carboplatin	AUC 6	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W		3
Cisplatin	75	≥ 4 hrs	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 4 hrs	d1	Q3W		3
Carboplatin	AUC 6	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	200* → 125	90* → 60 mins	d1	QW		4
Cisplatin	100	≥ 4 hrs	d1	Q4W	2-6	

*1st dose 200 mg/m² then followed by 125 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	Min 6	3, 5
5-FU	1000	22-24 hrs	d1-4	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250 → 500	90* → 60 mins	d1	QW* → QW → Q2W		6
Docetaxel	75	1 hr	d1	Q3W	4	
Cisplatin	75	≥ 4 hrs	d1	Q3W	4	

*1st dose 400 mg/m² and 2nd dose 250 mg/m² QW then followed by 500 mg/m² Q2W

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250 → 500	90* → 60 mins	d1	QW* → QW → Q2W		15
Docetaxel	75	1 hr	d1	Q3W	4	
Carboplatin	AUC 5	1 hr	d1	Q3W	4	

*1st dose 400 mg/m² and 2nd dose 250 mg/m² QW then followed by 500 mg/m² Q2W

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Cisplatin	100	≥ 4 hrs	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Carboplatin	AUC 5	1 hr	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	2	16, 17
Cisplatin	75	≥ 4 hrs	d1	Q3W	2	
Followed by						
Cetuximab	400* → 250	90* → 60 mins	d1	QW		
Cisplatin	75	≥ 4 hrs	d1	Q3W	4	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	2	16, 17
Carboplatin	AUC 6	1 hr	d1	Q3W	2	
Followed by						
Cetuximab	400* → 250	90* → 60 mins	d1	QW		
Carboplatin	AUC 6	1 hr	d1	Q3W	4	

*1st dose 400 mg/m² then followed by 250 mg/m²

Single Agents

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3-4W		7, 8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 3 hrs	d1	QW	6	9

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	100	1 hr	d1	Q3W		10

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	1000	22-24 hrs	d1	Q3W		8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Methotrexate	40	≥ 30 mins	d1	QW		11, 12

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	Min 7	13

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	500	2 hrs	d1	Q2W	2	25

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	d1-14	Q3W	Min 2	14

Useful in Certain Circumstances

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1, 8, 15	Q4W		23
Paclitaxel	80	≥ 1 hr	d1, 8, 15	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	500	2 hrs	d1	Q2W		24
Docetaxel	50	1 hr	d1	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		22
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q6W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan-nxki	5.4 mg/kg	90 mins	d1	Q3W		26

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Erdaftinib	8 mg PO QD				27

參考文獻

1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
2. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188.
3. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
4. Burtneß B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-8654.
5. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 1992;10:1245-1251.
6. Guigay J, Fayette J, Dillies A-F, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial

- GORTEC 2008-03 [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract 5505.
7. Burthese B, Goldwasser MA, Flood W, et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-8654.
 8. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
 9. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta OtoLaryngol 2009;129:1294-1299.
 10. Catimell G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533-537.
 11. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864-1871
 12. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1245-51.
 13. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007 Jun 1;25(16):2171-7.
 14. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102:1687-1691.
 15. Joel Guigay UK, Ricard Mesia, Nadejda Vintonenko, Jean Bourhis, Anne Auperin. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma. Journal of Clinical Oncology 2015.
 16. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13:35-46.
 17. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
 18. Rischin D, Harrington KJ, Greil R, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M

- HNSCC). *J Clin Oncol* 2019;37(suppl)6000-6000.
19. Burtneß B, Harrington KJ, Greil R, et al. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). ESMO 2018 Congress
20. Burtneß B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet*. (2019) 394:1915–28. doi: 10.1016/s0140-6736(19)32591-7
21. Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. *Lancet Oncol*. 2021 Jun;22(6):883-892.
22. Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: Final results of CheckMate 651. *J Clin Oncol* 2023;41:2166-2180.
23. Okada T, Okamoto I, Sato H, Ito T, Miyake K, Tsukahara K. Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma. *In Vivo*. 2021 Mar-Apr;35(2):1253-1259. doi: 10.21873/invivo.12376. PMID: 33622928; PMCID: PMC8045122.
24. Posch D, Fuchs H, Kornek G, Grah A, Pammer J, Aretin MB, Fuereder T. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. *Sci Rep*. 2016 Sep 6;6:32946. doi: 10.1038/srep32946. PMID: 27597175; PMCID: PMC5011715.
25. Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m² for patients with recurrent or metastatic head and neck squamous cell cancer. *J Natl Compr Canc Netw* 2012;10:1391-1398.
26. Meric-Bernstam F, Makker V, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. *J Clin Oncol*. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. PMID: 37870536; PMCID: PMC10730032.
27. Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. *Lancet Oncol* 2023;24:925-935.

《 鼻咽癌抗癌藥物治療指引 》

115 年版與上一版差異

114 年版 修訂日 113/12/30	115 年版 修訂日 114/12/08
審視無異動	

《鼻咽癌抗癌藥物治療指引》

Nasopharynx Carcinoma

Chemoradiation Followed by Adjuvant Chemotherapy

Cisplatin + RT followed by Cisplatin/5-FU

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3 with RT	1
Followed by						
Cisplatin	80	≥ 4 hrs	d1	Q4W	3 after RT	
5-FU	1000	22-24 hrs	d1-4	Q4W	3 after RT	

Carboplatin + RT followed by Carboplatin/5-FU

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	1	Q3W	3-5 with RT	2
Followed by						
Carboplatin	AUC 5	1 hr	1	Q3W	2 after RT	
5-FU	1000	22-24 1 hrs	1-4	Q3W	2 after RT	

Cisplatin + RT without adjuvant chemotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	7	3

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W	During RT	11
UFUR	800 mg* PO		d1-14	Q2W	During RT	
Leucovorin	60 mg PO		d1-14	Q2W	During RT	

*Or 300 mg/m²**After definitive chemoradiotherapy ± induction chemotherapy**

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	650 PO BID			For 1 year	17

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	2	18
5-FU	400	22-24 hrs	d1-4	Q4W	2	
Leucovorin	90	22-24 hrs	d1-4	Q4W	2	

Reirradiation + Concurrent Systemic Therapy**For patients with HF-IMRT**

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3 before RT	15, 16
Gemcitabine	1000	30 mins	d1, 8	Q3W	3 before RT	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q3W	3 before RT	15, 16
Gemcitabine	1000	30 mins	d1, 8	Q3W	3 before RT	
Followed by						
Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

For patients with SF-IMRT

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3 before RT	15, 16
5-Fu	1000	22-24 hrs	d1-4	Q3W	3 before RT	
Followed by						
Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q3W	3 before RT	15, 16
5-Fu	1000	22-24 hrs	d1-4	Q3W	3 before RT	
Followed by						
Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

Induction/Sequential Chemotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q3W	3	14
Gemcitabine	1000	30 mins	d1, 8	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	70	1 hr	d1	Q3W	3	4
Cisplatin	75	≥ 4 hrs	d1	Q3W	3	
5-FU	1000	22-24 hrs	d1-4	Q3W	3	
Followed by Cisplatin	100	≥ 4 hrs	d1	Q3W	With RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	60	1 hr	d1	Q3W	3	12
Cisplatin	60	≥ 4 hrs	d1	Q3W	3	
5-FU	600	22-24 hrs	d1-5	Q3W	3	
Followed by Cisplatin	100	≥ 4 hrs	d1	Q3W	With RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	2	5
Cisplatin	75	≥ 4 hrs	d1	Q3W	2	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	With RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	6
5-FU	1000	22-24 hrs	d1-4	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	7 during RT	7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	60-75	≥ 30 mins	d1	Q4W	3	8
Mitomycin	10	≥ 5 mins	d1	Q4W	Cycle 1, 3 only	
Cisplatin	60-100	≥ 4 hrs	d1	Q4W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	3	9
5-FU	1000	22-24 hrs	d1-4	Q4W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	2	18
5-FU	600	22-24 hrs	d1-4	Q4W	2	
Leucovorin	90	22-24 hrs	d1-4	Q4W	2	

Following induction, agents to be used with concurrent chemoradiation typically include weekly cisplatin or carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	7	10

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	≥ 30 mins	d1	QW	6 (Max 7)	13

參考文獻

1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *J Clin Oncol*. 1998 ;16:1310-1317.
2. Dechaphunkul T, Pruegsanusak K, Sangthawan D, et al. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. *Head Neck Oncol*. 2011;3:30.
3. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. *Lancet Oncol*. 2012;13:163-171.
4. Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. *Cancer Chemother Pharmacol*. 2010;65:589-595.
5. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. *J Clin Oncol*. 2009;27:242-249.
6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 2007;357(17):1705-1715.
7. A Hellenic Cooperative Oncology Group phase II study. *Strahlenther Onkol*. 2005;181:223-230.
8. Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. *J Clin Oncol*. 2001;19:4305-4313.
9. Muhyi al-Sarraf, Martine Leblanc, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *J Clin Oncol* 1998; 16: 1310-1317.
10. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst*. 2005 Apr 6;97(7):536-539.
11. Concurrent chemoradiotherapy using biweekly cisplatin/tegafur plus uracil/leucovorin in stage III nasopharyngeal carcinoma. *J Clin Oncol*. 2005 23(16): 5510
12. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised

- controlled trial. *Lancet Oncol* 2016; 17: 1509–20.
13. Ou D, Blanchard P, Khoury CE, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. *Oral Oncology* 62 (2016) 114–121.
 14. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. *N Engl J Med.* (2019) 381:1124–35.
 15. Lee VHF, Kwong DL, Leung T-W, et al. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma. *Eur Arch Otorhinolaryngol* 2017;274:1067-1078.
 16. Kong F, Zhou J, Du C, et al. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. *BMC Cancer* 2018;18:1139.
 17. Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. *Lancet* 2021;398:303-313.
 18. Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. *Cancer.* 1994 Jan 15;73(2):247-52. doi: 10.1002/1097-0142(19940115)73:2<247::aid-cnrc2820730203>3.0.co;2-7. PMID: 8293384.

Recurrent, Unresectable, or Metastatic Disease

First-line Therapy

Preferred Regimens

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	20-30*	≥ 2 hrs	d1-3	Q3W	Max 6	5
Gemcitabine	1000	30 mins	d1, 8	Q3W	Max 6	

*80 mg/m² in divided doses on 3 days

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	4-6	18
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	
Followed by Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q3W	4-6	19
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	
Followed by Nivolumab	240 mg	≥ 30 mins	d1	Q3W		

Other Recommended Regimens

Combination Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	65	1 hr	d1	Q3W		1
Carboplatin	AUC 6	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	Min 6	2
Cisplatin	75	≥ 4 hrs	d1	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W	Min 6	2
Paclitaxel	175	≥ 3 hrs	d1	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	Min 6	2, 3
5-FU	1000	22-24 hrs	d1-4	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90 → 60 mins	d1	QW	Max 8	4
Carboplatin	AUC 5	1 hr	d1	Q3W		

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	Max 8	15
Carboplatin	AUC 5	1 hr	d1	Q3W		

Cisplatin/gemcitabine + PD-1 inhibitor

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		16, 17
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q3W		16, 17
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	

Single Agents

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3-4W	Min 4	6, 7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W		14

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 1 hr	d1	QW	6	8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	100	1 hr	d1	Q3W		9

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	1000	22-24 hrs	d1	Q3W		7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Methotrexate	40	≥ 30 mins	d1	QW		10, 11

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		12

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	d1-14	Q3W	Min 2	13

參考文獻

1. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188.
2. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.

3. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. *J Clin Oncol* 1992;10:1245-1251.
4. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *J Clin Oncol* 2005;23:3568-3576.
5. Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. *J Cancer Res Clin Oncol* 2012 Oct;138(10):1717-25.
6. Burthess B, Goldwasser MA, Flood W, et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. *J Clin Oncol* 2005;23:8646-8654.
7. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 1992;10:257-263.
8. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. *Acta Otolaryngol* 2009;129:1294-1299.
9. Catimell G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. *Ann Oncol* 1994;5:533-537.
10. Stewart JS, Cohen EE, Licita L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. *J Clin Oncol* 2009;27:1864-1871.
11. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. *J Clin Oncol*. 1992 Aug;10(8):1245-51.
12. Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. *Cancer Chemother Pharmacol*. 2008;61:33-8. Epub 2007 Mar 20.
13. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. *Br J Cancer*

- 2010;102:1687-1691.
14. Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. *Cancer Treat Rep* 1987;71:732-736.
 15. Leong S-S, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. *Cancer*. 2005;103(3):569-575.
 16. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2021;22:1162-1174.
 17. Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. *Nat Med* 2021;27:1536-1543.
 18. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2021;22:1162-1174.
 19. Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. *Nat Med* 2021;27:1536-1543.